Datwyler, a globally recognized leader in high-quality elastomer components for injectable drug delivery systems, has commenced serial production and supply of premium components for prefilled syringes used in GLP-1 (glucagon-like peptide-1) receptor agonist therapies – one of the fastest-growing segments in the injectable drug market.
Following the successful completion of all development and validation milestones, these components are now being delivered under Datwyler's stringent FirstLine® manufacturing standard and will be integrated into an injection device for a GLP-1 drug. Datwyler is committed to a consistent and scalable increase in delivery volume. GLP-1 receptor agonists play an increasingly vital role in diabetes care and are demonstrating strong potential in the management of obesity, reinforcing their strategic importance within the broader healthcare landscape.
Strategic investments drive market leadership
This milestone highlights Datwyler's strengthened market position and its role as a key enabler of advanced injectable therapeutics. The company's long-term investments in global manufacturing infrastructure, product portfolio diversification, and enhanced customer support are now bearing fruit, positioning Datwyler as a preferred partner for globally leading pharmaceutical companies.
Datwyler is actively engaged with a broad network of current and prospective partners, supporting the advancement and commercialization of innovative GLP-1 therapies through strategic collaborations and supply relationships. Increasingly engaged at earlier stages of the development lifecycle for complex pharmaceutical projects, Datwyler is functioning as a proactive and value-added partner to its clientele.
Well-positioned for sustained growth in injectable therapies
With GLP-1 therapies exemplifying the strong mid-term growth potential in injectable pharmaceuticals, Datwyler is well-positioned to benefit from continued market expansion. The segment is characterized by high entry barriers and substantial unmet medical needs – factors that enhance the value of reliable, high-performance component suppliers. By delivering system-critical components with precision and consistency, Datwyler supports its pharmaceutical partners to minimize risks and enhance therapeutic outcomes, ultimately contributing to improved patient care worldwide.
Enquiries
Guido Unternährer
Head of Corporate Communications & Investor Relations
guido.unternaehrer@datwyler.com+41 41 875 19 00
Healthcare